

Natasha Kyprianou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6565138/publications.pdf>

Version: 2024-02-01

72
papers

1,820
citations

257101

24
h-index

288905

40
g-index

74
all docs

74
docs citations

74
times ranked

3562
citing authors

#	ARTICLE	IF	CITATIONS
1	Anoikis and EMT: Lethal "Liaisons" during Cancer Progression. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 155-168.	0.2	139
2	Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. <i>Communications Biology</i> , 2020, 3, 374.	2.0	112
3	Mechanisms of Therapeutic Resistance in Prostate Cancer. <i>Current Oncology Reports</i> , 2017, 19, 13.	1.8	103
4	Profiling Prostate Cancer Therapeutic Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 904.	1.8	96
5	Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2014, 10, 588-595.	2.6	87
6	Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. <i>Cancer Research</i> , 2016, 76, 912-926.	0.4	71
7	Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. <i>Cancers</i> , 2020, 12, 2984.	1.7	69
8	Mechanisms navigating the TGF- β 2 pathway in prostate cancer. <i>Asian Journal of Urology</i> , 2015, 2, 11-18.	0.5	59
9	PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. <i>Carcinogenesis</i> , 2014, 35, 2592-2601.	1.3	58
10	Profiles of Radioresistance Mechanisms in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 39-67.	0.2	58
11	Inflammation in prostate cancer progression and therapeutic targeting. <i>Translational Andrology and Urology</i> , 2015, 4, 455-63.	0.6	55
12	CD151- β 3 \int 1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. <i>Oncotarget</i> , 2015, 6, 29675-29693.	0.8	53
13	N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. <i>Molecular Oncology</i> , 2015, 9, 628-639.	2.1	52
14	Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 84-90.	1.2	49
15	TGF- β 2 receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. <i>Prostate</i> , 2019, 79, 31-43.	1.2	46
16	Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance. <i>Prostate</i> , 2017, 77, 1583-1591.	1.2	36
17	Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. <i>Scientific Reports</i> , 2020, 10, 1292.	1.6	35
18	Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 123-158.	1.9	34

#	ARTICLE	IF	CITATIONS
19	The Promise of Novel Molecular Markers in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23897-23908.	1.8	33
20	Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e86238.	1.1	32
21	Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. <i>Asian Journal of Urology</i> , 2019, 6, 82-90.	0.5	32
22	Epithelial-mesenchymal transition in prostatic disease. <i>Future Oncology</i> , 2015, 11, 3197-3206.	1.1	26
23	Aberrant TGF- β 2 Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis. <i>Endocrinology</i> , 2017, 158, 1612-1622.	1.4	26
24	Personalization of prostate cancer therapy through phosphoproteomics. <i>Nature Reviews Urology</i> , 2018, 15, 483-497.	1.9	25
25	COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer. <i>European Urology Focus</i> , 2020, 6, 1086-1096.	1.6	24
26	Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 82-90.	0.2	24
27	Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. <i>Human Pathology</i> , 2016, 57, 68-77.	1.1	22
28	Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10131.	1.8	22
29	Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 78507-78519.	0.8	21
30	A tale of two trials: The impact of 5 α -reductase inhibition on prostate cancer (Review). <i>Oncology Letters</i> , 2014, 8, 1391-1396.	0.8	20
31	Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 783-792.	0.8	20
32	Association between chronic kidney disease and COVID-19-related mortality in New York. <i>World Journal of Urology</i> , 2021, 39, 2987-2993.	1.2	19
33	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. <i>Nature Communications</i> , 2022, 13, 669.	5.8	19
34	Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 746-754.	3.9	18
35	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
36	Pseudouridine as a novel biomarker in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 63-71.	0.8	17

#	ARTICLE	IF	CITATIONS
37	ASK-ing EMT not to spread cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2731-2732.	3.3	14
38	Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. International Journal of Molecular Sciences, 2021, 22, 2100.	1.8	13
39	Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study. Clinical Genitourinary Cancer, 2021, 19, 405-416.	0.9	13
40	The Rapid Coronavirus Antibody Test: Can We Improve Accuracy?. Frontiers in Medicine, 2020, 7, 569.	1.2	12
41	Extracellular vesicles carry distinct proteo-transcriptomic signatures that are different from their cancer cell of origin. IScience, 2022, 25, 104414.	1.9	11
42	Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. European Urology Open Science, 2020, 20, 1-11.	0.2	10
43	Molecular tracing of prostate cancer lethality. Oncogene, 2020, 39, 7225-7238.	2.6	10
44	The Resilient Child: Sex-Steroid Hormones and COVID-19 Incidence in Pediatric Patients. Journal of the Endocrine Society, 2020, 4, bvaa106.	0.1	10
45	Role of α - and β -adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease. Cell Communication and Signaling, 2021, 19, 78.	2.7	10
46	Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 572.e1-572.e11.	0.8	9
47	Therapeutic challenges in renal cell carcinoma. American Journal of Clinical and Experimental Urology, 2015, 3, 77-90.	0.4	9
48	Cell death under epithelial \rightarrow mesenchymal transition control in prostate cancer therapeutic response. International Journal of Urology, 2018, 25, 318-326.	0.5	8
49	Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2019, 7, 188-202.	0.4	8
50	Repurposing of α 1-Adrenoceptor Antagonists: Impact in Renal Cancer. Cancers, 2020, 12, 2442.	1.7	7
51	Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients. Journal of Personalized Medicine, 2021, 11, 1061.	1.1	7
52	Does Gender Matter in Academic Surgery? Author and Mentor Gender Impact Publication Citations in Surgical Research. Urology, 2021, 157, 64-70.	0.5	6
53	Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. Frontiers in Oncology, 2022, 12, 759153.	1.3	5
54	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 734963.	1.3	4

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 RNA Detected in Abdominal Insufflation Samples During Laparoscopic Surgery. <i>European Urology</i> , 2021, 81, 125-125.	0.9	4
56	Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. <i>Prostate</i> , 2020, 80, 926-937.	1.2	3
57	TGF- β 2 Conveys Undesirable Side Effects of Androgen Depletion. <i>Endocrinology</i> , 2016, 157, 4206-4208.	1.4	2
58	COVID-19 in patients with and without cancer: Examining differences in patient characteristics and outcomes. , 2021, 2, 25-32.		2
59	Kinases and CHIPS sign-off personalization of therapy. <i>Nature Reviews Urology</i> , 2016, 13, 636-637.	1.9	1
60	Emmprin is a Biomarker of Prostate Cancer Progression in TRAMP Mice. <i>FASEB Journal</i> , 2007, 21, A621.	0.2	1
61	Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 183-198.	0.8	1
62	Talin1 Promotes Prostate Cancer Invasion and Metastasis via AKT Signaling and Anoikis Resistance. <i>Nature Precedings</i> , 2009, , .	0.1	0
63	Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelialâ€mesenchymal transition. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 403-416.	1.2	0
64	Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-cell Analysis. <i>European Urology</i> , 2021, 79, 161-162.	0.9	0
65	Homeless Cells Escape Death and Deliver Lethal Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	0
66	Doxazosinâ€derived DZâ€3 Compound Enhances Apoptotic Ability of Maspinâ€sensitized Prostate Cancer Cells. <i>FASEB Journal</i> , 2007, 21, A247.	0.2	0
67	Androgen Receptor Regulation by Microtubuleâ€targeting Chemotherapeutics in Prostate Cancer. <i>FASEB Journal</i> , 2012, 26, 999.1.	0.2	0
68	Nuclear spindles pave the way to metastasis. <i>Oncotarget</i> , 2018, 9, 12544-12545.	0.8	0
69	Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11645.	1.8	0
70	AUTHOR REPLY. <i>Urology</i> , 2021, 157, 70.	0.5	0
71	Age-Related Differences in Clinical and Psychosocial Predictors of Unmet Needs in Bladder Cancer Survivors. <i>Innovation in Aging</i> , 2021, 5, 282-282.	0.0	0
72	Prostate MRI percentage tumor involvement or â€PIâ€RADS percentâ€as a predictor of adverse surgical pathology. <i>Prostate</i> , 2022, , .	1.2	0